Differential expression of MART-1 in primary and metastatic melanoma lesions

Toshiro Kageshita, Yutaka Kawakami, Shunji Hirai, Tomomichi Ono

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Twenty-eight primary and 29 metastatic melanoma lesions and 18 pigmented nevi lesions were analyzed by using the immunoperoxidase reaction with anti- MART-1 and anti-gp100 monoclonal antibodies (mAbs). The MART-1 was expressed in 28, 29, and 18, and gp100 was expressed in 27, 28, and eight of these lesions, respectively. Intensity and percentage of stained cells with anti- MART-1 mAb were stronger and higher than those with anti-gp100 mAb. MART-1 was expressed homogeneously in primary melanoma and pigmented nevi, whereas it was heterogeneously expressed in metastatic melanoma lesions. The level of expression of MART-1 in primary melanoma lesions did not correlate with any clinicopathologic parameters. These results suggest that anti-MART-1 mAb is a useful tool for immunohistochemical analysis of melanocytic lesions and also is useful for patient's selection and monitoring of antigen-loss variants in clinical trials with the MART-1-based immunotherapy.

Original languageEnglish
Pages (from-to)460-465
Number of pages6
JournalJournal of Immunotherapy
Volume20
Issue number6
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Melanoma
Pigmented Nevus
Physiologic Monitoring
Immunotherapy
Patient Selection
Monoclonal Antibodies
Clinical Trials
Antigens

Keywords

  • gp100
  • MART-1
  • Melanocytic tumor

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Kageshita, T., Kawakami, Y., Hirai, S., & Ono, T. (1997). Differential expression of MART-1 in primary and metastatic melanoma lesions. Journal of Immunotherapy, 20(6), 460-465.

Differential expression of MART-1 in primary and metastatic melanoma lesions. / Kageshita, Toshiro; Kawakami, Yutaka; Hirai, Shunji; Ono, Tomomichi.

In: Journal of Immunotherapy, Vol. 20, No. 6, 1997, p. 460-465.

Research output: Contribution to journalArticle

Kageshita, T, Kawakami, Y, Hirai, S & Ono, T 1997, 'Differential expression of MART-1 in primary and metastatic melanoma lesions', Journal of Immunotherapy, vol. 20, no. 6, pp. 460-465.
Kageshita, Toshiro ; Kawakami, Yutaka ; Hirai, Shunji ; Ono, Tomomichi. / Differential expression of MART-1 in primary and metastatic melanoma lesions. In: Journal of Immunotherapy. 1997 ; Vol. 20, No. 6. pp. 460-465.
@article{136ec2b6182d44e5b711d39eef4026d6,
title = "Differential expression of MART-1 in primary and metastatic melanoma lesions",
abstract = "Twenty-eight primary and 29 metastatic melanoma lesions and 18 pigmented nevi lesions were analyzed by using the immunoperoxidase reaction with anti- MART-1 and anti-gp100 monoclonal antibodies (mAbs). The MART-1 was expressed in 28, 29, and 18, and gp100 was expressed in 27, 28, and eight of these lesions, respectively. Intensity and percentage of stained cells with anti- MART-1 mAb were stronger and higher than those with anti-gp100 mAb. MART-1 was expressed homogeneously in primary melanoma and pigmented nevi, whereas it was heterogeneously expressed in metastatic melanoma lesions. The level of expression of MART-1 in primary melanoma lesions did not correlate with any clinicopathologic parameters. These results suggest that anti-MART-1 mAb is a useful tool for immunohistochemical analysis of melanocytic lesions and also is useful for patient's selection and monitoring of antigen-loss variants in clinical trials with the MART-1-based immunotherapy.",
keywords = "gp100, MART-1, Melanocytic tumor",
author = "Toshiro Kageshita and Yutaka Kawakami and Shunji Hirai and Tomomichi Ono",
year = "1997",
language = "English",
volume = "20",
pages = "460--465",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Differential expression of MART-1 in primary and metastatic melanoma lesions

AU - Kageshita, Toshiro

AU - Kawakami, Yutaka

AU - Hirai, Shunji

AU - Ono, Tomomichi

PY - 1997

Y1 - 1997

N2 - Twenty-eight primary and 29 metastatic melanoma lesions and 18 pigmented nevi lesions were analyzed by using the immunoperoxidase reaction with anti- MART-1 and anti-gp100 monoclonal antibodies (mAbs). The MART-1 was expressed in 28, 29, and 18, and gp100 was expressed in 27, 28, and eight of these lesions, respectively. Intensity and percentage of stained cells with anti- MART-1 mAb were stronger and higher than those with anti-gp100 mAb. MART-1 was expressed homogeneously in primary melanoma and pigmented nevi, whereas it was heterogeneously expressed in metastatic melanoma lesions. The level of expression of MART-1 in primary melanoma lesions did not correlate with any clinicopathologic parameters. These results suggest that anti-MART-1 mAb is a useful tool for immunohistochemical analysis of melanocytic lesions and also is useful for patient's selection and monitoring of antigen-loss variants in clinical trials with the MART-1-based immunotherapy.

AB - Twenty-eight primary and 29 metastatic melanoma lesions and 18 pigmented nevi lesions were analyzed by using the immunoperoxidase reaction with anti- MART-1 and anti-gp100 monoclonal antibodies (mAbs). The MART-1 was expressed in 28, 29, and 18, and gp100 was expressed in 27, 28, and eight of these lesions, respectively. Intensity and percentage of stained cells with anti- MART-1 mAb were stronger and higher than those with anti-gp100 mAb. MART-1 was expressed homogeneously in primary melanoma and pigmented nevi, whereas it was heterogeneously expressed in metastatic melanoma lesions. The level of expression of MART-1 in primary melanoma lesions did not correlate with any clinicopathologic parameters. These results suggest that anti-MART-1 mAb is a useful tool for immunohistochemical analysis of melanocytic lesions and also is useful for patient's selection and monitoring of antigen-loss variants in clinical trials with the MART-1-based immunotherapy.

KW - gp100

KW - MART-1

KW - Melanocytic tumor

UR - http://www.scopus.com/inward/record.url?scp=0030785491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030785491&partnerID=8YFLogxK

M3 - Article

C2 - 9409451

AN - SCOPUS:0030785491

VL - 20

SP - 460

EP - 465

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 6

ER -